8-K: Intelligent Bio Solutions Inc. Announces Strong Fiscal 2024 Results with 148% Revenue Growth

Intelligent Bio Solutions Inc. reported a 148% increase in full-year revenue, reaching $3.11 million, and a 64% increase in fourth-quarter revenue, totaling $0.73 million.

Summary

• Intelligent Bio Solutions Inc. (INBS) announced its financial results for the fiscal fourth quarter and full year ended June 30, 2024.
• The company's full-year revenue reached $3.11 million, a 148% increase compared to the previous fiscal year.
• Fourth-quarter revenue was $0.73 million, a 64% increase year-over-year.
• As of June 30, 2024, INBS had $6.30 million in cash.
• The company reported a 20% increase in cartridge sales and a 26% increase in reader sales for the fiscal year.
• The net loss attributable to INBS for fiscal year 2024 was $10.16 million, compared to $10.63 million in the prior fiscal year.
• Loss from operations was $10.28 million for the 2024 fiscal year, compared to $12.59 million in the prior fiscal year.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong revenue growth and progress on key milestones. While the company is still operating at a loss, the significant revenue increase and strategic initiatives suggest a promising future. The sentiment is very positive but tempered by the current losses.

Positives

• The company experienced significant revenue growth, with a 148% increase for the full year and a 64% increase in the fourth quarter.
• The company has a strong cash position of $6.30 million.
• There was a 20% increase in cartridge sales and a 26% increase in reader sales, indicating growing adoption of their technology.
• The company has expanded its global footprint into new markets such as New Zealand.
• The company has secured new partnerships and customers, demonstrating market acceptance of its product.
• The company has made progress on its FDA 510(k) submission, with the completion of the in-clinic portion of its PK study.
• The company has achieved a reduction in operating expenses of $1.53 million.

Negatives

• The company reported a net loss of $10.16 million for the fiscal year 2024.
• The company's loss from operations was $10.28 million for the fiscal year 2024.
• The company experienced a decrease in fair value gain on the revaluation of financial instruments compared to the prior fiscal year.

Risks

• The company is still operating at a loss, indicating a need to achieve profitability.
• The company's future success depends on securing regulatory approvals, particularly the FDA 510(k) clearance.
• The company's growth is dependent on continued market demand and expansion into new geographical regions.
• The company faces risks associated with the development and commercialization of its drug and diagnostic tests.

Future Outlook

The company remains on track for its planned FDA 510(k) submission in the fourth calendar quarter of this year and anticipates opportunities in 2025. The company plans strategic geographical expansion to enter new markets and grow its customer network.

Management Comments

• Harry Simeonidis, President and CEO at INBS, stated that the fiscal 2024 results reflect the dedication of the team to drive the business forward.
• Spiro Sakiris, CFO at INBS, commented that they closed out fiscal 2024 with strong results and have ensured revenue growth through concentrated expansion of their footprint.

Industry Context

The company operates in the medical technology sector, specifically focusing on drug screening solutions. The demand for rapid, non-invasive testing is growing, and INBS is positioning itself to capitalize on this trend. The company's focus on workplace safety and employee well-being aligns with current industry trends.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the 148% revenue growth is significant and suggests strong market traction compared to industry averages.
• The company's focus on fingerprint sweat analysis is a unique approach compared to traditional drug testing methods, potentially giving them a competitive edge.
• The company's expansion into new markets and partnerships with various companies indicates a proactive approach to growth, which is a positive sign compared to companies with a more limited reach.
• The company's progress towards FDA 510(k) clearance is a critical step for market acceptance in the US, which is a common benchmark for medical device companies.

Stakeholder Impact

• Shareholders will be encouraged by the strong revenue growth and progress towards FDA approval.
• Employees will likely be motivated by the company's positive performance and expansion.
• Customers will benefit from the company's innovative and efficient drug screening solutions.
• Suppliers may see increased demand for their products and services as the company grows.
• Creditors may view the company as a more stable and reliable borrower due to its improved financial performance.

Next Steps

• The company plans to complete the full PK study in the third calendar quarter of 2024.
• The company is on track for its planned FDA 510(k) submission in the fourth calendar quarter of this year.
• The company will focus on strategic geographical expansion to enter new markets.
• The company will continue to grow its customer network.

Key Dates

Keywords

drug screening, fingerprint testing, medical technology, revenue growth, FDA 510(k), pharmacokinetic study, cartridge sales, reader sales, non-invasive testing, ISO 13485